Khyati Shah, PhD

Title(s)Postdoctoral Scholar, Bioengineering
SchoolSchool of Pharmacy
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Shah KN, Bandyopadhyay S. Targeting the evolution of drug resistance in lung cancer. Mol Cell Oncol. 2019; 6(5):e1603092. PMID: 31528688.
      View in: PubMed
    2. Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, Harding TC, McCormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nat Med. 2019 01; 25(1):111-118. PMID: 30478424.
      View in: PubMed
    3. Donnella HJ, Webber JT, Levin RS, Camarda R, Momcilovic O, Bayani N, Shah KN, Korkola JE, Shokat KM, Goga A, Gordan JD, Bandyopadhyay S. Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer. Nat Chem Biol. 2018 08; 14(8):768-777. PMID: 29942081.
      View in: PubMed
    4. Hu HM, Zhao X, Kaushik S, Robillard L, Barthelet A, Lin KK, Shah KN, Simmons AD, Raponi M, Harding TC, Bandyopadhyay S. A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance. Cell Rep. 2018 Apr 17; 23(3):918-929. PMID: 29669295.
      View in: PubMed
    5. Shah KN, Wilson EA, Malla R, Elford HL, Faridi JS. Targeting Ribonucleotide Reductase M2 and NF-?B Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer. Mol Cancer Ther. 2015 Nov; 14(11):2411-21. PMID: 26333382.
      View in: PubMed
    6. Shah KN, Mehta KR, Peterson D, Evangelista M, Livesey JC, Faridi JS. AKT-induced tamoxifen resistance is overturned by RRM2 inhibition. Mol Cancer Res. 2014 Mar; 12(3):394-407. PMID: 24362250.
      View in: PubMed
    7. KN Shah, JS Faridi.Voyagers and their aids: The role of interactions between tumor and endothelial cells in brain metastasis. 2012.
    8. Shah KN, Faridi JS. Estrogen, tamoxifen, and Akt modulate expression of putative housekeeping genes in breast cancer cells. J Steroid Biochem Mol Biol. 2011 Jul; 125(3-5):219-25. PMID: 21420492.
      View in: PubMed
    9. Shah KN, Peterson D, Kowanetz K, and Evangelista M.Mapping out the "altered" metabolic network in pancreatic cancer by integration of methylation profiling and RNA-seq Genentech Inc.
    10. Khyati Niral Shah, David Peterson, Marie Evangelista, and Jesika Faridi.RRM2: a key contributor in tamoxifen resistance in breast cancer.
    11. Shah KN, Faridi JS.Identification of altered genes in tamoxifen resistant breast cancer.
    12. Khyati N. Shah, Howard L. Elford, and Jesika S. Faridi.The ribonucleotide reductase inhibitor Didox reverses tamoxifen resistance in breast cancer cells.
    13. Khyati Niral Shah and Jesika S. Faridi.. Estrogen, tamoxifen, and Akt modulate expression of putative housekeeping genes in breast cancer cells.
    14. Shah KN, and Evangelista, M .Mutations in IDH1 enhances sensitivity to LDHA inhibitors, Genentech.